Trade Names:Hydrocodone/Homatropine- Syrup 5 mg hydrocodone bitartrate and 1.5 mg homatropine methylbromide
Trade Names:Tussigon- Tablets 5 mg hydrocodone bitartrate and 1.5 mg homatropine methylbromide
Suppresses cough reflex; stimulates opiate receptors in the CNS and peripherally blocks pain impulse generation.
AtropineInhibits action of acetylcholine or other cholinergic stimuli at postganglionic cholinergic receptors.
Symptomatic relief of cough.
Hypersensitivity to any component of product.
PO 1 tablet or 1 tsp (5 mL) of syrup every 4 to 6 h (max, 6 tablets or 6 tsp in 24 h).
Children 6 to 12 yr of agePO ½ tablet or ½ tsp (2.5 mL) every 4 to 6 h (max, 3 tablets or 3 tsp in 24 h).
Measure and administer prescribed dose of syrup using dosing syringe, dosing spoon, or dosing cup.
Store tablets and syrup at controlled room temperature (59° to 86°F). Keep syrup tightly capped and protect from freezing.
CNS depressant effects may be increased.
MAOIs, tricyclic antidepressantsEffects of these agents or hydrocodone may be increased.
None well documented.
Sedation; drowsiness; mental clouding; lethargy; impairment of mental and physical performance; anxiety; fear; dysphoria; dizziness; psychic dependence; mood change.
Skin rash; pruritus.
Nausea; vomiting; constipation.
Ureteral spasm; spasm of vesicle sphincters; urinary retention.
Dose-related respiratory depression.
Category C .
Undetermined.
Safety and efficacy in children younger than 6 yr of age not established.
Use with caution in elderly or debilitated patients and in those with hepatic or renal function impairment, hypothyroidism, Addison disease, prostatic hypertrophy or urethral stricture, asthma, and narrow-angle glaucoma.
Diagnosis may be obscured.
Hydrocodone has abuse potential; may be habit forming.
Diagnosis of adverse reactions may be obscured; respiratory depression properties and capacity to elevate cerebrospinal fluid pressure of hydrocodone may be markedly exaggerated.
Respiratory depression, extreme somnolence progressing to stupor and coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension, apnea, circulatory collapse, cardiac arrest, death.
Copyright © 2009 Wolters Kluwer Health.